{"id":"placebo-comparator-arm-b-control","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL3647440","moleculeType":"Small molecule","molecularWeight":"509.57"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo comparators are inert substances or sham procedures used in randomized controlled trials to establish the efficacy of an investigational drug by comparison. They help distinguish genuine drug effects from natural disease progression, regression to the mean, and placebo response. This is a standard control arm rather than an active pharmaceutical agent.","oneSentence":"A placebo comparator arm provides no active therapeutic intervention and serves as a control baseline in clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:47.562Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07220785","phase":"PHASE3","title":"Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-03-13","conditions":"Generalized Lipodystrophy","enrollment":28},{"nctId":"NCT06564818","phase":"PHASE3","title":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","status":"RECRUITING","sponsor":"Cybin IRL Limited","startDate":"2024-12-17","conditions":"Major Depressive Disorder","enrollment":220},{"nctId":"NCT05531565","phase":"PHASE2, PHASE3","title":"A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus","status":"RECRUITING","sponsor":"Biogen","startDate":"2022-09-13","conditions":"Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus","enrollment":450},{"nctId":"NCT04123795","phase":"PHASE3","title":"A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2020-01-21","conditions":"Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis, Mixed Guttate/Plaque Psoriasis","enrollment":49},{"nctId":"NCT07363694","phase":"PHASE2, PHASE3","title":"A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease","status":"RECRUITING","sponsor":"Pfizer","startDate":"2026-02-11","conditions":"Moderate to Severe Chronic Obstructive Pulmonary Disease","enrollment":1156},{"nctId":"NCT06782490","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity","status":"RECRUITING","sponsor":"Celgene","startDate":"2025-06-05","conditions":"Multiple Sclerosis Spasticity","enrollment":200},{"nctId":"NCT06788756","phase":"PHASE2, PHASE3","title":"L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML","status":"RECRUITING","sponsor":"Moleculin Biotech, Inc.","startDate":"2025-03-12","conditions":"Acute Myeloid Leukaemia (AML)","enrollment":312},{"nctId":"NCT06629779","phase":"PHASE3","title":"A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-10-22","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":900},{"nctId":"NCT07489599","phase":"PHASE1","title":"A Study of QLH2405 in Healthy Participants and Participants With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-03","conditions":"Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)","enrollment":68},{"nctId":"NCT01946204","phase":"PHASE3","title":"A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2013-10-14","conditions":"Prostatic Neoplasms","enrollment":1207},{"nctId":"NCT06334016","phase":"EARLY_PHASE1","title":"Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream","status":"NOT_YET_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-05-15","conditions":"Cannabis Dependence","enrollment":60},{"nctId":"NCT04924608","phase":"PHASE3","title":"Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-11-19","conditions":"Neurofibromatosis 1, Plexiform Neurofibroma (PN)","enrollment":145},{"nctId":"NCT06793397","phase":"PHASE3","title":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","status":"RECRUITING","sponsor":"Cybin IRL Limited","startDate":"2025-12-10","conditions":"Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder","enrollment":330},{"nctId":"NCT06788990","phase":"PHASE2, PHASE3","title":"FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC","status":"RECRUITING","sponsor":"Bicara Therapeutics","startDate":"2025-01-28","conditions":"Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":650},{"nctId":"NCT05996835","phase":"PHASE2","title":"Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-01-18","conditions":"Acute Kidney Injury Due to Sepsis","enrollment":320},{"nctId":"NCT07200089","phase":"PHASE1","title":"Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-05-31","conditions":"Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory","enrollment":40},{"nctId":"NCT07486115","phase":"PHASE1","title":"A Study to Test How Different Doses of BI 3814916 Are Tolerated by Healthy People","status":"NOT_YET_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2026-04-07","conditions":"Healthy","enrollment":136},{"nctId":"NCT06828861","phase":"PHASE3","title":"ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial","status":"SUSPENDED","sponsor":"Aardvark Therapeutics, Inc.","startDate":"2024-12-20","conditions":"Hyperphagia, Prader-Willi Syndrome","enrollment":90},{"nctId":"NCT06852222","phase":"PHASE3","title":"A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-06-04","conditions":"Leukemia, Myeloid, Acute","enrollment":600},{"nctId":"NCT07225621","phase":"PHASE2","title":"Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma","status":"RECRUITING","sponsor":"Alpheus Medical, Inc.","startDate":"2026-01-28","conditions":"Glioblastoma, GBM","enrollment":103},{"nctId":"NCT05126277","phase":"PHASE3","title":"Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-07-14","conditions":"Lupus Nephritis","enrollment":462},{"nctId":"NCT05492500","phase":"PHASE2","title":"A Study of Ponsegromab in People With Heart Failure","status":"TERMINATED","sponsor":"Pfizer","startDate":"2022-09-26","conditions":"Heart Failure","enrollment":455},{"nctId":"NCT07281937","phase":"PHASE2","title":"A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities","status":"ACTIVE_NOT_RECRUITING","sponsor":"Verdiva Bio Dev Limited","startDate":"2025-11-25","conditions":"Obesity, Overweight","enrollment":206},{"nctId":"NCT02947347","phase":"PHASE3","title":"Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2017-01-23","conditions":"Follicular Lymphoma","enrollment":445},{"nctId":"NCT04404283","phase":"PHASE3","title":"Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2020-08-20","conditions":"Diffuse Large B-cell Lymphoma","enrollment":238},{"nctId":"NCT06784349","phase":"PHASE1","title":"ALN-APOC3 in Adult Participants With Dyslipidemia","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2025-01-27","conditions":"Dyslipidemia","enrollment":32},{"nctId":"NCT05811351","phase":"PHASE2","title":"A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2023-03-06","conditions":"Geographic Atrophy","enrollment":305},{"nctId":"NCT07011719","phase":"PHASE3","title":"Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma","status":"RECRUITING","sponsor":"Arcus Biosciences, Inc.","startDate":"2025-09-08","conditions":"Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma","enrollment":720},{"nctId":"NCT06200467","phase":"PHASE1","title":"A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2024-03-13","conditions":"Overweight, Obesity","enrollment":110},{"nctId":"NCT07007312","phase":"PHASE3","title":"Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML","status":"RECRUITING","sponsor":"Kura Oncology, Inc.","startDate":"2025-09-26","conditions":"Acute Myeloid Leukemia (AML)","enrollment":1300},{"nctId":"NCT01900743","phase":"PHASE2","title":"Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2013-06-05","conditions":"Sarcoma","enrollment":219},{"nctId":"NCT06785012","phase":"PHASE2","title":"A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-12-26","conditions":"Depressive Disorder, Major","enrollment":124},{"nctId":"NCT06941844","phase":"PHASE3","title":"A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","startDate":"2025-04-14","conditions":"Major Depressive Disorder","enrollment":149},{"nctId":"NCT06809595","phase":"PHASE3","title":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","status":"RECRUITING","sponsor":"Definium Therapeutics US, Inc.","startDate":"2025-01-29","conditions":"Generalized Anxiety Disorder","enrollment":250},{"nctId":"NCT06134648","phase":"PHASE1, PHASE2","title":"Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-11-01","conditions":"Respiratory Syncytial Virus Infection, Healthy Volunteers, Human Metapneumovirus","enrollment":646},{"nctId":"NCT06234501","phase":"NA","title":"Testing the Efficacy of 100mg Vitamin-B6 Daily for Sensory Reactivity in Autism","status":"RECRUITING","sponsor":"University of Reading","startDate":"2024-11-08","conditions":"Autism","enrollment":40},{"nctId":"NCT05350072","phase":"PHASE3","title":"Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-07-28","conditions":"Sjogren Syndrome","enrollment":276},{"nctId":"NCT05349214","phase":"PHASE3","title":"Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-08-04","conditions":"Sjogren Syndrome","enrollment":506},{"nctId":"NCT07091630","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP","status":"RECRUITING","sponsor":"argenx","startDate":"2025-09-16","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy","enrollment":160},{"nctId":"NCT04314531","phase":"PHASE3","title":"Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2020-07-01","conditions":"Active Psoriatic Arthritis","enrollment":296},{"nctId":"NCT07304843","phase":"PHASE1, PHASE2","title":"A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive Dysfunction","status":"RECRUITING","sponsor":"Umecrine Cognition AB","startDate":"2023-04-14","conditions":"Primary Biliary Cholangitis (PBC)","enrollment":84},{"nctId":"NCT06323928","phase":"PHASE2","title":"A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lundbeck A/S","startDate":"2024-04-01","conditions":"Migraine","enrollment":874},{"nctId":"NCT03847428","phase":"PHASE3","title":"Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-04-29","conditions":"Hepatocellular Carcinoma","enrollment":908},{"nctId":"NCT06869551","phase":"PHASE3","title":"A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-03-13","conditions":"Juvenile Psoriatic Arthritis","enrollment":60},{"nctId":"NCT07389044","phase":"PHASE1","title":"A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B","status":"RECRUITING","sponsor":"IntegerBio","startDate":"2026-02-20","conditions":"Chronic Hepatitis B Virus Infection","enrollment":90},{"nctId":"NCT07028853","phase":"PHASE3","title":"This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-09-28","conditions":"Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer","enrollment":1000},{"nctId":"NCT06109779","phase":"PHASE3","title":"Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-12-04","conditions":"Biliary Tract Cancer","enrollment":757},{"nctId":"NCT07246863","phase":"PHASE2","title":"Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC","status":"RECRUITING","sponsor":"CatalYm GmbH","startDate":"2025-10-07","conditions":"Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor","enrollment":131},{"nctId":"NCT06937931","phase":"PHASE2","title":"A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults","status":"RECRUITING","sponsor":"Ipsen","startDate":"2025-06-30","conditions":"Cervical Dystonia","enrollment":132},{"nctId":"NCT04873362","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-05-04","conditions":"Breast Cancer","enrollment":1188},{"nctId":"NCT07075718","phase":"PHASE2, PHASE3","title":"Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant","status":"RECRUITING","sponsor":"Glaukos Corporation","startDate":"2025-06-12","conditions":"Glaucoma","enrollment":610},{"nctId":"NCT07437586","phase":"PHASE2","title":"Topical GHK-Cu Gel for Acute Skin Wound Healing","status":"RECRUITING","sponsor":"Hudson Biotech","startDate":"2026-02-02","conditions":"Acute Standardized Cutaneous Wounds (Punch-biopsy Wounds)","enrollment":60},{"nctId":"NCT06608927","phase":"PHASE3","title":"Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arcus Biosciences, Inc.","startDate":"2024-12-13","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":610},{"nctId":"NCT06741228","phase":"PHASE3","title":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)","status":"RECRUITING","sponsor":"Definium Therapeutics US, Inc.","startDate":"2024-12-11","conditions":"Generalized Anxiety Disorder","enrollment":200},{"nctId":"NCT06578247","phase":"PHASE3","title":"Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2024-11-19","conditions":"Leukemia","enrollment":700},{"nctId":"NCT06930625","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs","status":"RECRUITING","sponsor":"Debiopharm International SA","startDate":"2025-11-26","conditions":"Acromegaly","enrollment":119},{"nctId":"NCT06136741","phase":"PHASE2","title":"A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nektar Therapeutics","startDate":"2023-11-15","conditions":"Moderate to Severe Atopic Dermatitis","enrollment":396},{"nctId":"NCT07098988","phase":"PHASE2","title":"Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC","status":"RECRUITING","sponsor":"CatalYm GmbH","startDate":"2025-08-01","conditions":"Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor","enrollment":107},{"nctId":"NCT06790121","phase":"PHASE2","title":"A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-01-30","conditions":"Dermatitis Atopic","enrollment":150},{"nctId":"NCT05211895","phase":"PHASE3","title":"A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-02-18","conditions":"Non-Small Cell Lung Cancer","enrollment":860},{"nctId":"NCT01649765","phase":"PHASE2","title":"Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-09-07","conditions":"Systemic Lupus Erythematosus","enrollment":93},{"nctId":"NCT03866187","phase":"PHASE1, PHASE2","title":"Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2019-03-28","conditions":"Hepatitis B, Chronic","enrollment":236},{"nctId":"NCT07016412","phase":"PHASE2","title":"A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD","status":"RECRUITING","sponsor":"Verona Pharma plc","startDate":"2025-07-31","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":480},{"nctId":"NCT03217422","phase":"PHASE2, PHASE3","title":"ADCC Mediated B-Cell dEpletion and BAFF-R Blockade","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-02-15","conditions":"Autoimmune Hepatitis","enrollment":68},{"nctId":"NCT07377136","phase":"NA","title":"Influence of the Urolithin A on the Population With BMI Higher Than 30 During Restricted Eating.","status":"ENROLLING_BY_INVITATION","sponsor":"Charles University, Czech Republic","startDate":"2025-10-08","conditions":"Obesity & Overweight","enrollment":100},{"nctId":"NCT07419815","phase":"NA","title":"IV Lidocaine Infusion Versus Placebo for Pain Control in Staging Laparoscopy Cases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shaukat Khanum Memorial Cancer Hospital & Research Centre","startDate":"2025-12-03","conditions":"Side Effects of Opoid Consumption","enrollment":62},{"nctId":"NCT06977581","phase":"PHASE2","title":"A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-05-20","conditions":"Asthma","enrollment":252},{"nctId":"NCT06682975","phase":"PHASE1","title":"A Research Study Looking at the Safety of Single and Multiple Doses of ZP9830 and How it Works in the Body of Healthy Participants","status":"RECRUITING","sponsor":"Zealand Pharma","startDate":"2024-11-12","conditions":"Healthy Volunteers","enrollment":124},{"nctId":"NCT06544616","phase":"PHASE2","title":"A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2024-07-22","conditions":"Preclinical Alzheimer's Disease","enrollment":498},{"nctId":"NCT07406477","phase":"PHASE2","title":"The PROTECT-HIE Trial","status":"NOT_YET_RECRUITING","sponsor":"University of Alberta","startDate":"2026-05-01","conditions":"Hypoxic-ischemic Encephalopathy (HIE)","enrollment":40},{"nctId":"NCT03949855","phase":"PHASE2","title":"Belimumab With Rituximab for Primary Membranous Nephropathy","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-03-06","conditions":"Membranous Nephropathy, Nephrotic Syndrome","enrollment":58},{"nctId":"NCT07187531","phase":"PHASE2","title":"SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes","status":"RECRUITING","sponsor":"SAb Biotherapeutics, Inc.","startDate":"2025-11-25","conditions":"Type 1 Diabetes","enrollment":159},{"nctId":"NCT05534984","phase":"PHASE3","title":"Study of Tecovirimat for Human Mpox Virus","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-09-08","conditions":"MPOX","enrollment":719},{"nctId":"NCT03375047","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-05-10","conditions":"Cystic Fibrosis","enrollment":42},{"nctId":"NCT06071767","phase":"PHASE1, PHASE2","title":"Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-04-01","conditions":"HIV-1-infection","enrollment":36},{"nctId":"NCT07392125","phase":"PHASE3","title":"Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes","status":"NOT_YET_RECRUITING","sponsor":"Achieve Life Sciences","startDate":"2026-05-15","conditions":"Vaping Cessation","enrollment":800},{"nctId":"NCT03274492","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-11-16","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":1000},{"nctId":"NCT07387198","phase":"PHASE2","title":"Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab","status":"NOT_YET_RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2026-02-28","conditions":"Merkel Cell Carcinoma, Stage I, Merkel Cell Carcinoma, Stage II, Neoadjuvant Immunotherapy","enrollment":135},{"nctId":"NCT07379203","phase":"PHASE2","title":"ValgaNciclovIR for CMV Viraemia in AdvaNced HIV diseAse","status":"NOT_YET_RECRUITING","sponsor":"Wits Health Consortium (Pty) Ltd","startDate":"2026-02-01","conditions":"Cytomegalovirus (CMV) Infection","enrollment":130},{"nctId":"NCT07372144","phase":"PHASE3","title":"Creatine and Cognitive Health in Patients With Early-stage Breast Cancer During and After Chemotherapy Treatment","status":"NOT_YET_RECRUITING","sponsor":"D'Or Institute for Research and Education","startDate":"2026-08-01","conditions":"Breast Cancer","enrollment":227},{"nctId":"NCT07373301","phase":"PHASE2","title":"Phase IIa/b Trial of PvCS/Montanide ISA-51 Malaria Vaccine in Adults in Chocó, Colombia","status":"NOT_YET_RECRUITING","sponsor":"Malaria Vaccine and Drug Development Center","startDate":"2026-01-19","conditions":"Plasmodium Vivax Malaria, Plasmodium Vivax Infection, Malaria Prevention","enrollment":72},{"nctId":"NCT04828161","phase":"PHASE2, PHASE3","title":"A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-05-10","conditions":"COVID-19","enrollment":407},{"nctId":"NCT05221840","phase":"PHASE3","title":"A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-02-07","conditions":"Non-Small Cell Lung Cancer","enrollment":1051},{"nctId":"NCT07363057","phase":"PHASE2","title":"A Study to Evaluate the Effects of the Combination of GI-102 With GIB-7 on Biomarkers of Aging in Healthy Adults and Cancer Survivors","status":"RECRUITING","sponsor":"GI Innovation, Inc.","startDate":"2026-01","conditions":"Cancer Survivors, Healthy Participant, Elderly","enrollment":15},{"nctId":"NCT05217628","phase":"PHASE2, PHASE3","title":"An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Noema Pharma AG","startDate":"2022-01-11","conditions":"Trigeminal Neuralgia","enrollment":166},{"nctId":"NCT07145164","phase":"PHASE2","title":"Interleukin-15 to Promote Post-ART Control of HIV","status":"ENROLLING_BY_INVITATION","sponsor":"Michael Peluso, MD","startDate":"2025-08-19","conditions":"HIV","enrollment":20},{"nctId":"NCT06694740","phase":"PHASE2, PHASE3","title":"Effect of Interferon Gamma as a Treatment for Post-aggressive Immunosuppression in Intensive Care Units, a Randomized Bayesian Double-blind Controlled Trial Versus Placebo","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-01-12","conditions":"Post-aggressive Immunosuppression, Adult Patients Admitted to Intensive Care With Initial Severity (SOFA of the First 24 Hours Post-admission ≥ 6, Adult Under Mechanical Ventilation, and Presenting an mHLA-DR Less Than 8,000AB/C","enrollment":170},{"nctId":"NCT06404086","phase":"PHASE2","title":"RECOVER-SLEEP: Platform Protocol","status":"COMPLETED","sponsor":"Duke University","startDate":"2024-07-31","conditions":"Long COVID, Long COVID-19, Hypersomnia","enrollment":830},{"nctId":"NCT06837480","phase":"NA","title":"Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema","status":"RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2026-01-15","conditions":"Head and Neck Cancer, Lymphedema of the Head and Neck","enrollment":150},{"nctId":"NCT06055985","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2023-11-17","conditions":"Parkinson Disease","enrollment":207},{"nctId":"NCT04543617","phase":"PHASE3","title":"A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-09-28","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":760},{"nctId":"NCT06527404","phase":"PHASE3","title":"A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2024-07-18","conditions":"Prurigo Nodularis","enrollment":469},{"nctId":"NCT07349771","phase":"PHASE2","title":"Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial","status":"NOT_YET_RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-01-31","conditions":"Hematopoietic and Lymphatic System Neoplasm","enrollment":72},{"nctId":"NCT03778957","phase":"PHASE3","title":"A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-11-30","conditions":"Hepatocellular Carcinoma","enrollment":724},{"nctId":"NCT07176208","phase":"PHASE1","title":"Clinical Study to Evaluate the Effects of Oral Delta-9-tetrahydrocannabinol (Δ9-THC) With and Without Alcohol on Perception and Driving Performance in Healthy Adults","status":"RECRUITING","sponsor":"Food and Drug Administration (FDA)","startDate":"2025-12-29","conditions":"Cannabis, Drug Effects, Driving Performance","enrollment":48},{"nctId":"NCT05169567","phase":"PHASE3","title":"Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2022-03-11","conditions":"Breast Neoplasm, Neoplasm Metastasis","enrollment":368},{"nctId":"NCT05704738","phase":"PHASE3","title":"A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Amgen","startDate":"2023-04-20","conditions":"Atopic Dermatitis","enrollment":532},{"nctId":"NCT04314544","phase":"PHASE3","title":"Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2020-07-01","conditions":"Active Psoriatic Arthritis","enrollment":508},{"nctId":"NCT04987307","phase":"PHASE2","title":"Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis","status":"TERMINATED","sponsor":"Amgen","startDate":"2022-01-31","conditions":"Ulcerative Colitis","enrollment":221},{"nctId":"NCT04765059","phase":"PHASE3","title":"A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-09-12","conditions":"Non-small Cell Lung Cancer","enrollment":98}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo Comparator: Arm B - Control","genericName":"Placebo Comparator: Arm B - Control","companyName":"Syntara","companyId":"syntara","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Arm B of the Placebo Comparator is a control group that receives a placebo, and it is used in clinical trials studying various conditions such as Diabetes Mellitus, Type 1, and Irritable Bowel Syndrome With Diarrhea. The control group is also used in trials involving traumatic brain injury and brain conditions, and it is administered via closed-loop (CL) or other methods, such as insulin monotherapy or sitagliptin.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}